BA Merger Sub

BioAtla is a clinical-stage biopharmaceutical company specializing in the development of Conditionally Active Biologics (CABs) for the treatment of solid tumors. The company's proprietary CAB platform utilizes the unique acidic microenvironment of tumors to selectively activate therapeutic antibodies, thereby enhancing anti-tumor activity while minimizing systemic toxicity and off-target effects on healthy tissues. BioAtla's diverse pipeline includes antibody-drug conjugates (ADCs) and bispecific T-cell engagers targeting validated and novel antigens such as AXL, ROR2, and CTLA-4. As of early 2026, the company is advancing its lead candidate, ozuriftamab vedotin (Oz-V), into Phase 3 registrational trials for head and neck cancer. BioAtla is headquartered in San Diego and maintains strategic collaborations to expand the reach of its CAB technology across various oncology indications.